Modifications and structure–activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists

Bioorganic & Medicinal Chemistry Letters
2002.0

Abstract

To improve water solubility and to study structure-activity relationships, we modified the structure of the pyrimidine nucleus of each of a series of potent ET(A) antagonists, 3a and 4a, at the 2-position. In a previous study, each of these antagonists showed an extremely high affinity for the ET(A) receptor in porcine aortic membrane (IC(50) 3a; < 0.001 nM, 4a; 0.0039 nM). Two modification methods, one being the addition of organolithium followed by DDQ oxidation and the other being the nucleophilic substitution of 2-(methylsulfonyl)pyrimidine, were applied individually to synthesize 2-substituted-4-sulfonamidopyrimidine derivatives. The introduction of aryl, heteroaryl, alkyl, amino, alkoxy, or alkylthio groups into the 2-position varied the affinity. Derivatives with hydrophilic groups at the 2-position showed higher water solubility but tended to reduce the affinity for the ET(A) receptor.

Knowledge Graph

Similar Paper

Modifications and structure–activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists
Bioorganic &amp; Medicinal Chemistry Letters 2002.0
Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 2. Sulfonamide-Based ET<sub>A</sub>/ET<sub>B</sub> Mixed Antagonists
Journal of Medicinal Chemistry 1997.0
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists
Bioorganic &amp; Medicinal Chemistry Letters 2003.0
Halogen substitution at the isoxazole ring enhances the activity of N-(isoxazolyl)sulfonamide endothelin antagonists
Bioorganic &amp; Medicinal Chemistry Letters 1996.0
Discovery and Synthesis of (S)-3-[2-(3,4-Dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic Acid (LU 302872), a Novel Orally Active Mixed ET<sub>A</sub>/ET<sub>B</sub> Receptor Antagonist
Journal of Medicinal Chemistry 1999.0
Discovery and synthesis of a potent sulfonamide ETB selective antagonist
Bioorganic &amp; Medicinal Chemistry Letters 2000.0
Synthesis and biological evaluation of 4′-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists
Bioorganic &amp; Medicinal Chemistry 2012.0
Discovery and Structure-Activity Relationships of Sulfonamide ETA-Selective Antagonists
Journal of Medicinal Chemistry 1995.0
Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of N-[[2‘-[[(4,5-Dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1‘-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), A Highly Potent and Orally Active ET<sub>A</sub> Selective Antagonist
Journal of Medicinal Chemistry 2003.0
Synthesis and structure-activity relationships of pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists
Journal of Medicinal Chemistry 1987.0